Olecranon bursitis secondary to Mycobacterium kansasii infection in a patient receiving infliximab for Behcet's disease.
We present a case of Mycobacterium kansasii olecranon bursitis in a woman with known immunosuppression secondary to the treatment received for her Behçet's disease. We found only one other case report of olecranon bursitis caused by M. kansasii in the literature, which, unlike our case, presented in an immunocompetent adult following trauma. This case extends the range of opportunistic mycobacterial infections that are associated with anti-tumour necrosis factor therapy.
Malkin
Joanne
J
Clinical Microbiology, Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust, Leicester LE1 5WW, UK.
Shrimpton
Anna
A
Clinical Immunology and Allergy Unit, Northern General Hospital, Sheffield S5 7AU, UK.
Wiselka
Martin
M
Infectious Diseases Department, Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust, Leicester LE1 5WW, UK.
Barer
Michael R
MR
Clinical Microbiology, Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust, Leicester LE1 5WW, UK.
Duddridge
Michael
M
Department of Immunology, Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust, Leicester LE1 5WW, UK.
Perera
Nelun
N
Clinical Microbiology, Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust, Leicester LE1 5WW, UK.
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000995:Antitubercular Agents / Q000627:therapeutic use; D001528:Behcet Syndrome / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D002062:Bursitis / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology*; D004550:Elbow; D004977:Ethambutol / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D000069285:Infliximab; D008875:Middle Aged; D009165:Mycobacterium Infections, Nontuberculous / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology*; D019909:Mycobacterium kansasii / Q000302:isolation & purification; D012293:Rifampin / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000995:Antitubercular Agents; D004977:Ethambutol; D000069285:Infliximab; D012293:Rifampin